# Decitabine for Poor Graft Function Post Allo-HSCT

> **NCT05907499** · PHASE3 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 76 (estimated)

## Conditions studied

- Poor Graft Function

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Granulocyte Colony-Stimulating Factor
- **DRUG:** Thrombopoietin Receptor Agonist
- **DRUG:** Recombinant human erythropoietin

## Key facts

- **NCT ID:** NCT05907499
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05907499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05907499, "Decitabine for Poor Graft Function Post Allo-HSCT". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05907499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*